We discussed a number of things including:
1. The battle against COVID and the progress on vaccines and treatments
2. The state of innovation in biotech and pharma industries
3. Forecasts for healthcare in 2021 and beyond
Fred is a Director with the private equity firm, Warburg Pincus. He is also a Board member of Amgen, Intrexon, Modernizing Medicine, Theramex and Vertice. Fred is the former Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation. P
rior to joining Schering-Plough in April 2003, he was Chairman and Chief Executive Officer of Pharmacia Corporation – a company that was formed in March 2000 as a result of the merger of Monsanto and Pharmacia and Upjohn. Hassan joined Pharmacia & Upjohn as Chief Executive Officer in 1997.
Previously, Hassan was Executive Vice President of Wyeth, with responsibility for its pharmaceutical and medical products business. He was elected to Wyeth's Board of Directors in 1995. Earlier in his career, Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals business.
Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School. Hassan has chaired significant pharmaceutical industry organizations including The Pharmaceutical Research and Manufacturers of America (PhRMA) and The International Federation of Pharmaceutical Manufacturers Associations (IFPMA).
Fred's book, "Reinvent - A Leader's Playbook for Serial Success," was published in 2013 by Wiley and has been discussed in many global organizations including the World Bank. In 2014, a CNBC panel named Hassan to a list of those who have had the most profound impact on the world of business in the previous quarter century.